By skyforbes Iambic, San diego based biotech company, just secured 100M$ to advance clinical trials of cancer drugs discovered entirely through AI. This is a significant milestone which shiws AI;s potential beyind the discovery phase into clinicall validation with real patients,
The companys AI platform identities small molecules with improved safety and efficacy profiles. Their lead candidate IAM1363 is designed to selectively inhibit HER2 (a cancer driving protien) wwhile avoiding the toxicity issues that are there with other drugs. ini this class. This kind of selective targeting is exactky where AI seems to be taking an advantage.
Thats some serious AI driving drug discovery.